Incyte Corporation Stock News

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.

Finding promising stocks is harder, given that the S&P 500 has risen by about one-third over 12 months.

The allure of penny stocks is understandable. For literally just a few dollars, you can control hundreds, if not thousands, of shares.

The global oncology ecosystem is at a pivotal juncture. Significant advancements in discovery, development, and delivery of novel cancer treatments are enhancing patient outcomes.

While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.

The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biote

Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opz

Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima

Incyte (INCY) came out with quarterly earnings of $1.06 per share, missing the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $0.62 per share a year ago.

Evaluate the expected performance of Incyte (INCY) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics

Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.

Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp.